Legacy Non-public Belief Co. minimize its place in Bristol-Myers Squibb (NYSE:BMY – Free Report) by 14.4% within the third quarter, Holdings Channel.com reviews. The agency owned 9,441 shares of the biopharmaceutical firm’s inventory after promoting 1,593 shares in the course of the interval. Legacy Non-public Belief Co.’s holdings in Bristol-Myers Squibb had been value $488,000 on the finish of the latest quarter.
Quite a few different hedge funds have additionally lately made adjustments to their positions within the firm. Connectus Wealth LLC elevated its place in Bristol-Myers Squibb by 22.8% within the 4th quarter. Connectus Wealth LLC now owns 25,779 shares of the biopharmaceutical firm’s inventory valued at $1,323,000 after buying an extra 4,791 shares in the course of the interval. Symmetry Investments LP acquired a brand new stake in Bristol-Myers Squibb within the fourth quarter valued at $1,054,000. Wasatch Advisors LP raised its place in Bristol-Myers Squibb by 4.2% in the course of the 4th quarter. Wasatch Advisors LP now owns 87,375 shares of the biopharmaceutical firm’s inventory value $4,483,000 after buying an extra 3,500 shares over the last quarter. Ethic Inc. lifted its holdings in Bristol-Myers Squibb by 5.2% in the course of the 4th quarter. Ethic Inc. now owns 184,859 shares of the biopharmaceutical firm’s inventory value $9,485,000 after shopping for an extra 9,174 shares in the course of the interval. Lastly, Jacobi Capital Administration LLC grew its place in shares of Bristol-Myers Squibb by 0.8% within the 4th quarter. Jacobi Capital Administration LLC now owns 44,784 shares of the biopharmaceutical firm’s inventory valued at $2,298,000 after shopping for an extra 339 shares over the last quarter. 76.41% of the inventory is owned by institutional buyers and hedge funds.
Bristol-Myers Squibb Inventory Efficiency
BMY inventory opened at $52.48 on Wednesday. The enterprise has a 50 day shifting common of $49.43 and a 200-day shifting common of $46.34. The agency has a market cap of $106.38 billion, a PE ratio of -16.93, a P/E/G ratio of 12.96 and a beta of 0.46. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month excessive of $57.65. The corporate has a fast ratio of 1.02, a present ratio of 1.16 and a debt-to-equity ratio of two.86.
Bristol-Myers Squibb (NYSE:BMY – Get Free Report) final launched its earnings outcomes on Friday, July twenty sixth. The biopharmaceutical firm reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.64 by $0.43. The corporate had income of $12.20 billion for the quarter, in comparison with analysts’ expectations of $11.54 billion. Bristol-Myers Squibb had a optimistic return on fairness of 12.51% and a adverse web margin of 14.06%. The enterprise’s income for the quarter was up 8.7% in comparison with the identical quarter final 12 months. Throughout the identical interval within the earlier 12 months, the enterprise posted $1.75 EPS. As a bunch, sell-side analysts anticipate that Bristol-Myers Squibb will submit 0.77 earnings per share for the present 12 months.
Bristol-Myers Squibb Broadcasts Dividend
The enterprise additionally lately introduced a quarterly dividend, which can be paid on Friday, November 1st. Stockholders of report on Friday, October 4th can be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized foundation and a dividend yield of 4.57%. The ex-dividend date of this dividend is Friday, October 4th. Bristol-Myers Squibb’s dividend payout ratio is presently -77.42%.
Wall Avenue Analyst Weigh In
BMY has been the topic of various analyst reviews. TD Cowen raised their worth goal on Bristol-Myers Squibb from $53.00 to $59.00 and gave the inventory a “maintain” score in a analysis report on Monday. Cantor Fitzgerald reiterated a “impartial” score and set a $50.00 worth goal on shares of Bristol-Myers Squibb in a analysis report on Monday, September sixteenth. StockNews.com upgraded Bristol-Myers Squibb from a “purchase” score to a “strong-buy” score in a report on Monday, July twenty ninth. Barclays elevated their goal worth on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the inventory an “underweight” score in a analysis notice on Monday. Lastly, BMO Capital Markets restated a “market carry out” score and issued a $48.00 goal worth on shares of Bristol-Myers Squibb in a analysis notice on Monday, September twenty third. Two analysis analysts have rated the inventory with a promote score, 13 have given a maintain score, one has given a purchase score and one has issued a powerful purchase score to the corporate’s inventory. Primarily based on knowledge from MarketBeat.com, the corporate has a consensus score of “Maintain” and a mean goal worth of $53.43.
Verify Out Our Newest Inventory Report on BMY
Bristol-Myers Squibb Firm Profile
Bristol-Myers Squibb Firm discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical merchandise worldwide. It affords merchandise for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience ailments. The corporate’s merchandise embody Eliquis for discount in threat of stroke/systemic embolism in non-valvular atrial fibrillation, and for the remedy of DVT/PE; Opdivo for numerous anti-cancer indications, together with bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, abdomen and esophageal most cancers; Pomalyst/Imnovid for a number of myeloma; Orencia for energetic rheumatoid arthritis and psoriatic arthritis; and Sprycel for the remedy of Philadelphia chromosome-positive continual myeloid leukemia.
Featured Tales
Need to see what different hedge funds are holding BMY? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Free Report).
Obtain Information & Rankings for Bristol-Myers Squibb Day by day – Enter your electronic mail tackle under to obtain a concise day by day abstract of the most recent information and analysts’ scores for Bristol-Myers Squibb and associated corporations with MarketBeat.com’s FREE day by day electronic mail e-newsletter.